Mark Carvlin

Bio

Mark has unique experience integrating scientific development with business principles to maximize the marketability of new products. He had been instrumental in developing new imaging-related products, ranging from discovery to market place deployment in North America, Japan and Europe. He understands the fundamentals of accelerated development, project prioritization, expense control and organizational structuring. In a distinguished seven-year career with Bracco Diagnostics Inc. in Princeton New Jersey, Mark reported to the CEO and served as a Member of the Executive Committee and Chair of the Portfolio Management Team. Mark served as Bracco's chief technology liaison to key external and internal customers such as Group Purchasing Organizations, Columbia-HCA and the Health Care Financing Administration. At various times Mark was Senior Director of: Product Development & Planning; Government & Business Relations; and, Medical Services & Planning. Mark established a 12-person department encompassing the Strategic Market Development and New Product Development groups. Through his teams, he provided support for global initiatives including long-range product/portfolio forecasts and pipeline valuations. In that context, Mark established the Worldwide Technology Assessment function to monitor existing technologies as well as to identify emerging technologies that would provide new opportunities and secure competitive advantages. Mark established the Public Affairs and Government Relations function to nurture relationships with all of the company's external constituents, including government agencies and regulators. Mark also has hands-on experience as the Project Team Leader for development of 5 products. Prior to Bracco, Mark began his education at Holy Cross, obtaining a B.A. in Physics. He then obtained a Ph.D. in Biophysics from the Roswell Park Cancer Institute where he focused on novel photodynamic antineoplastic therapies. Mark then pursued a biomedical imaging Research Fellowship at the University of Pennsylvania and an NIH Postdoctoral Fellowship at the University of Rochester. His research encompassed the structural properties of synthetic oncogenes and the use of MRI to characterize pathophysiologic states. Mark has been the recipient of numerous awards, including NIH Research and Postdoctoral Fellowships, an American Cancer Society Research Grant and the Nugent Gold Medal.

Career

---

Mi3 Venture Partners Venture Partner Email: [email protected]